Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TRIM31 promotes AML progression, resistance to daunorubicin

Key clinical point: The oncogenic role of TRIM31 may provide therapeutic targets.

Major finding: The oncogenic role of TRIM31 in AML was mediated by the Wnt/beta-catenin pathway.

Study details: TRIM31 was assessed in 34 AML patients and 34 healthy volunteers using qRT-PCR.

Disclosures: The study was supported by the National Science Foundation of China and other agencies. No conflicts of interest statement was given.

Citation:

Xiao Y et al. Biosci Rep. 2020;doi.org/10.1042/BSR20194334. https://doi.org/10.1042/BSR20194334